Contemporary outcomes of mitral valve repair for degenerative disease in the era of increased penetrance of percutaneous mitral valve technology

• DOI: 10.1016/j.xjon.2022.11.004
• Publication Date: 2022-11-16T07:01:49Z
• Authors: Brittany G. Abt; Michael E. Bowdish; Ramsey S. Elsayed; Robbin Cohen; Markian Bojko; Alexander Vorperian; Michael Brown; Vaughn A. Starnes
• Keywords: Interquartile range; Cumulative incidence

The study objective was to evaluate the surgical outcomes of mitral valve repair in era percutaneous technology.We retrospectively reviewed 452 patients who underwent for degenerative disease between 2010 and 2021. Survival, reoperation, regurgitation recurrence were assessed using Cox regression, dichotomized those aged more than or less 60 years.Median age years (interquartile range) 52 (47-57) younger cohort 67 (63-73) older (P < .0001). Preoperative comorbidities leaflet pathology comparable groups. After adjustment sex, prior sternotomy, diabetes, atrial fibrillation, type repair, not associated with increased mortality (hazard ratio, 6.96, 95% confidence interval, 0.85-56.8, P = .07). Considering death as a competing outcome, cumulative incidence reoperation at 1, 3, 5 0.9%, 1.4%, 1.8% cohort, respectively, 2.7%, 4.0%, 5.1% respectively (subhazard 2.95, 0.84-10.4, .09). Cumulative moderate-severe greater 3.6%, 5.1%, 3.5%, 4.7% cohorts, 0.85, 0.29-2.50, .76). Subgroup analysis focusing on isolated repairs (n 388) showed equivalent results respect 5.31, 0.64-44.0, .12), 4.04, 0.89-18.4, .07), 0.98, 0.30-3.15, .97).Mitral continue be excellent, even low-risk years.